Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Elanco licenses canine pain drug

by Ann M. Thayer
May 2, 2016 | A version of this story appeared in Volume 94, Issue 18

Eli Lilly & Co.’s Elanco animal health division has licensed rights to a canine pain drug developed by Kansas-based Aratana Therapeutics. Approved by FDA in March, Galliprant is a noncyclooxygenase-inhibiting, nonsteroidal anti-inflammatory designed to control osteoarthritic pain and inflammation in dogs. Elanco is paying $45 million up front and up to $83 million in milestones. Aratana licensed the drug for animal use in 2011 from Japan’s RaQualia Pharma. Aratana says it should be available in the fall.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.